Added 24 days ago Drug news
FDA approves Nivestym biosimilar for neutropenia, chemotherapy infections and nonmyeloid malignancies, as Neupogen.- Pfizer.
Pfizer announced that the FDA has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the...
Added 1 month ago Drug news
Data from ADVANCE Phase III study of Rolontis shows non-inferiority to pegfilgrastim for management of severe neutropenia- - Spectrum Pharma.
Spectrum Pharmaceuticals, Inc. has announced detailed data from the ADVANCE Phase III study which showed that Rolontis had an absolute...
Added 2 months ago Drug news
FDA approves Fulphila a pegfilgrastim biosimilar for treatment of febrile neutropenia.- Mylan N.V. + Biocon.
Mylan N.V. and Biocon Ltd. announced that the FDA has approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
Febrile neutropaenia is the development of fever, often with other signs of infection, in a patient with neutropaenia, an abnormally low number of neutrophil granulocytes in the blood.
Added 8 years ago
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care.
Added 5 years ago
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.
Added 11 months ago
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Background: Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these...
Added 2 years ago